AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15640479
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein containing 99 mg isoflavones/d (in equol nonproducers)
Trial: 8789590
Drug: Pizotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifen (1 mg orally, administered 5 hours before exercise)
Trial: 31415381
Drug: Qingzhong (TDF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingzhong (TDF) 300mg once daily for 48 weeks
Trial: 31415381
Drug: Viread (TDF)
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Viread (TDF) 300mg once daily for 48 weeks
Trial: 23432466
Drug: NRTI-sparing regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI-sparing regimens (e.g., raltegravir plus darunavir/ritonavir)
Trial: 23432466
Drug: NRTI-based regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI-based regimens (e.g., tenofovir DF/emtricitabine plus darunavir/ritonavir)
Trial: 22108937
Drug: Adenosine 400
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine 400 μmol l(‐1) in antegrade cardioplegia
Trial: 22108937
Drug: Adenosine 400
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine 400 μmol l(‐1) in retrograde cardioplegia
Trial: 19158228
Drug: Moderate-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-protein diet (PRO) with 1.6 g/kg/d protein and <170 g/d carbohydrates
Trial: 8149056
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of oral steroid therapy
Trial: 23770179
Drug: ETC-1002 40
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETC-1002 40 mg
Trial: 23770179
Drug: ETC-1002 80
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETC-1002 80 mg
Trial: 20185616
Drug: 30 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 hours of robotic-assisted therapy combined with 30 hours of therapist-supervised repetitive task practice (RTP)
Trial: 20185616
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (combined therapy and RTP-only)
Trial: 18286595
Drug: L-acetylcarnitine (LAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-acetylcarnitine (LAC) 20-50 mg/kg/day
Trial: 14583175
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic treatment aiming at normal HbA1c levels
Trial: 10555125
Drug: Epirubicin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2 without G-CSF
Trial: 10555125
Drug: Epirubicin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2 with G-CSF
Trial: 10555125
Drug: Epirubicin pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin pharmacokinetics
Trial: 10555125
Drug: Epirubicin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2
Trial: 8724309
Drug: IVIG (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (intravenous immunoglobulin) at a dose between 1.5 and 2.0 g/kg/infusion (100 g maximum) bimonthly for the first 2 months, then monthly for up to 6 months
Trial: 8724309
Drug: IVIG (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (intravenous immunoglobulin) continued in the double-blind phase
Trial: 1761450
Drug: Tobramycin dosage
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin dosage regimens determined by a computerized pharmacokinetic predictive program (Group B)
Trial: 1761450
Drug: Tobramycin dosage
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin dosage regimens decided by clinicians based on pre-existing protocols (Group A)
Trial: 6750609
Drug: Local hyperthermia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local hyperthermia treatment (three 30-min insufflations of humidified air at 43 degrees C at a 2-hr interval)
Trial: 30070706
Drug: 20% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% sucrose solution applied 4 times per day
Trial: 30070706
Drug: 20% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% sucrose solution applied 8 times per day
Trial: 30070706
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0× sucrose treatment)
Trial: 26822022
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for treatment-experienced patients with cirrhosis
Trial: 19189088
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of bromazepam
Trial: 19189088
Drug: Nasogastric administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasogastric administration of bromazepam
Trial: 19189088
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of omeprazole
Trial: 19189088
Drug: Nasogastric administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasogastric administration of omeprazole
Trial: 19189088
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of paracetamol
Trial: 19189088
Drug: Nasogastric administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasogastric administration of paracetamol
Trial: 9882032
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg before breakfast (qAM)
Trial: 9882032
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg before dinner (qPM)
Trial: 9882032
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg before breakfast and dinner (b.d.)
Trial: 7924325
Drug: Vaginal rings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h
Trial: 7924325
Drug: Vaginal rings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h + transdermal estradiol at 50 micrograms/24h
Trial: 7924325
Drug: Vaginal rings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h + transdermal estradiol at 100 micrograms/24h
Trial: 7924325
Drug: Vaginal rings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal rings releasing levonorgestrel (L‐NOG)
Trial: 7924325
Drug: Vaginal rings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal rings releasing levonorgestrel (L‐NOG) + estradiol (50 or 100 micrograms/24h)
Trial: 2803900
Drug: Diphtheria/tetanus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria/tetanus vaccine
Trial: 1169086
Drug: Proximal gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal gastric vagotomy (P.G.V.) without drainage
Trial: 1169086
Drug: Proximal gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal gastric vagotomy (P.G.V.) with gastrojejunostomy
Trial: 14659974
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Pycnogenol for 12 weeks
Trial: 11180035
Drug: Intravenous tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tacrolimus (0.015 mg/kg)
Trial: 8127015
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no calcitriol treatment)
Trial: 28657604
Drug: Fruit fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit fiber consumption (≥8.8 g/day)
Trial: 25279689
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (treadmill training three times per week for 3 months) + vitamin B6 and Ca supplements
Trial: 25279689
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 and Ca supplements (control group)
Trial: 23865727
Drug: Zabofloxacin hydrochloride
RxNorm normalized name: Marbofloxacin
DrugBank: Zabofloxacin (DB12479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zabofloxacin hydrochloride 400 mg capsule (DW224a)
Trial: 23865727
Drug: Zabofloxacin aspartate
RxNorm normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zabofloxacin aspartate 488 mg tablet (DW224aa)
Trial: 22096523
Drug: Internet-based self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based self-management program involving weekly online monitoring of asthma control with self-treatment advice, remote Web communications, and Internet-based information
Trial: 19338148
Drug: Jianpi Wenshen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianpi Wenshen Recipe (JPWS) plus chemotherapy
Trial: 16782097
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human FSH (rhFSH) at high doses (300 IU on alternate days) for a period of >or=4 months
Trial: 27673505
Drug: Naloxone (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.25 μg/kg/h)
Trial: 18354844
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of natalizumab and interferon beta
Trial: 11528361
Drug: Oral E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2 valerate (2 mg) + cyproterone acetate (1 mg)
Trial: 11528361
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 (1.5 mg) + oral medroxyprogesterone acetate (5 mg)
Trial: 3819804
Drug: High-dose FAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose FAC chemotherapy (100% to 260% higher than standard FAC)
Trial: 3819804
Drug: Standard-dose FAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose FAC chemotherapy
Trial: 3819804
Drug: High-dose FAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose FAC chemotherapy
Trial: 29989857
Drug: Standard four‐field
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard four‐field radiation therapy (RT)
Trial: 17362050
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy approaches
Trial: 17362050
Drug: Newer cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer cytotoxic chemotherapies and biological agents
Trial: 9031445
Drug: Warfarin (adjusted-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (adjusted-dose, INR 2.0 to 3.0)
Trial: 8295037
Drug: Relaxation training
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation training (n = 25, 15-minute daily program at the workplace for 6 months)
Trial: 30138685
Drug: Midodrine (15–30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (15–30 mg/day) and albumin (40 g/15 days)
Trial: 25124829
Drug: Therapeutic alliance
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic alliance and therapist adherence in successful treatments
Trial: 25124829
Drug: Therapeutic alliance
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic alliance and therapist adherence in treatment failure
Trial: 16492320
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% 40 mL injected when nerve stimulation elicited a distal motor response
Trial: 16492320
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% 30 mL injected (7 mL to musculocutaneous nerve and 23 mL to median, ulnar or radial nerves)
Trial: 10857893
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) administered when monocytopenia (<150/microl) appeared on days 6 to 8 after chemotherapy (group A)
Trial: 10857893
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) administered when neutropenia (<1,000/microl) or leukopenia (<2,000/microl) appeared after chemotherapy (group B)
Trial: 8227484
Drug: Iodinated glycerol
RxNorm normalized name: iodinated glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodinated glycerol (60 mg four times daily; n = 16)
Trial: 30835643
Drug: Drug education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug education (Control)
Trial: 29934099
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg thrice daily
Trial: 27194199
Drug: Hydrocodone ER
RxNorm normalized name: hydrocodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone ER (15-90 mg every 12 hours)
Trial: 10618944
Drug: succinylcholine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 0.5 mg kg‐1
Trial: 10618944
Drug: succinylcholine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 0.25 mg kg‐1
Trial: 7546679
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg amoxicillin every 12 h for 10 days
Trial: 7546679
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg amoxicillin every 8 h for 10 days
Trial: 7546679
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg amoxicillin at 12 h before surgery
Trial: 7546679
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg amoxicillin at 8 h before surgery
Trial: 7546679
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg amoxicillin at 6 h before surgery
Trial: 7546679
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (acute and chronic sinusitis)
Trial: 2020925
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of calcitonin 0.5 mg by intradermic route
Trial: 2020925
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of calcitonin 0.5 mg
Trial: 7340377
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of morphine in 10 ml of saline (n = 15)
Trial: 7340377
Drug: 6‐8 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐8 ml of 0.5% bupivacaine with epinephrine (n = 17)
Trial: 7340377
Drug: 4‐6 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐6 ml of 0.5% bupivacaine with epinephrine
Trial: 7340377
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of morphine in 10 ml of saline
Trial: 28779933
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT‐i)
Trial: 25997550
Drug: Generic sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic sildenafil 50 mg film-coated tablets
Trial: 25997550
Drug: Viagra® 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viagra® 50 mg film-coated tablets (reference)
Trial: 19138577
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (amoxicillin, metronidazole, and omeprazole)
Trial: 22004229
Drug: 500 IU
RxNorm normalized name: Vitamin E 500 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 IU 1,25 dihydroxy vitamin D3 + calcium combination
Trial: 22004229
Drug: Triple DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple DMARD therapy + calcium alone
Trial: 16980380
Drug: Ramipril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (up to 15 mg per day)
Trial: 10397291
Drug: Sialic acid
RxNorm normalized name: Ganglioside monosialic acid antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sialic acid concentrations after 5 weeks of treatment
Trial: 8862204
Drug: Pamidronate (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (i.v. formulation given monthly)
Trial: 8862204
Drug: Oral formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulations of bisphosphonates
Trial: 2057277
Drug: Surfactant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant treatment (surfactant TA containing surfactant proteins B and C, no SP-A)
Trial: 2057277
Drug: Surfactant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant treatment (surfactant TA)
Trial: 30260821
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement with anorganic bovine bone and resorbable collagen barrier (Group A)
Trial: 30260821
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement without bone graft (Group B)
Trial: 23355182
Drug: Qigong intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qigong intervention (5 weekly classes over 5 or 6 weeks of radiotherapy)
Trial: 18808446
Drug: Oral delayed-release
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral delayed-release mesalazine (2.4 g/day and 4.8 g/day)
Trial: 12545143
Drug: Dipyridamole (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (300 mg/d for 3 days)
Trial: 11014886
Drug: Intraoral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoral appliance therapy (ISMAR)
Trial: 1592952
Drug: Drugs (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs (specific drugs not mentioned)
Trial: 27104984
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) lozenges, 2 per day for 3 weeks
Trial: 27104984
Drug: Placebo lozenges,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges, 2 per day for 3 weeks
Trial: 25180378
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules (taken twice daily for 12 months)
Trial: 25180378
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (taken twice daily for 12 months)
Trial: 14693066
Drug: L-OHP +
RxNorm normalized name: L-OHP
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-OHP + LV + 5-FU + VP-16 (treatment group)
Trial: 11200144
Drug: Infusional fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusional fluorouracil (5-FU) in combination with cisplatin (Platinol) or newer agents docetaxel (Taxotere) and irinotecan (Camptosar)
Trial: 8774625
Drug: Probucol (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (750 mg/day) for at least 30 days prior to PTCA (group P‐1)
Trial: 8774625
Drug: Probucol (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (750 mg/day) for less than 14 days prior to PTCA (group P‐2)
Trial: 8774625
Drug: Pravastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10 mg/day) for at least 30 days prior to PTCA (group V‐1)
Trial: 8774625
Drug: Pravastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10 mg/day) for less than 14 days prior to PTCA (group V‐2)
Trial: 1616359
Drug: Metronidazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (400 mg twice daily for weeks 0-8, then 400 mg three times a day for weeks 9-24)